Azulfidine

Quick links to important sections

Azulfidine

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azulfidine

Quick Facts

Property Description
Active Ingredient Sulfasalazine (Salicylazosulfapyridine)
Form Oral Tablets, Enteric-coated Oral Tablets
Pharmacological Class Disease-Modifying Antirheumatic Drug (DMARD), Anti-inflammatory Agent
General Purpose Long-term immunomodulation and reduction of chronic inflammation
Origin Synthetic Compound (Pro-drug)

The Core Identity: Azulfidine as a Prescription DMARD

Azulfidine is a widely recognized prescription drug containing the active ingredient Sulfasalazine, which is chemically known as Salicylazosulfapyridine. It is formally classified as both a Disease-Modifying Antirheumatic Drug (DMARD) and an anti-inflammatory agent. This dual classification signifies that the drug is designed to address the fundamental biological disease process over time, offering more than just temporary symptomatic relief. This synthetic compound is administered via the oral route and is available as standard tablets or specialized enteric-coated oral tablets, with the latter designed to minimize potential gastrointestinal irritation.

Composition and Origin: What is Sulfasalazine Made Of?

The active ingredient, Sulfasalazine, is a distinctive pro-drug molecule. This specialized structure means the compound is largely inactive when ingested but is designed to be split by enzymes in the lower digestive tract into two therapeutic parts: a sulfonamide derivative (sulfapyridine) and an aminosalicylate derivative, specifically 5-aminosalicylic acid (5-ASA). This pro-drug design is a key differentiating feature; its breakdown process ensures targeted delivery of the anti-inflammatory component while also introducing a systemic immunomodulator. The enteric-coated form further highlights this targeted approach, safeguarding the molecule until it reaches its intended site of action in the colon.

General Therapeutic Purpose: Why is Azulfidine Used?

The general purpose of Azulfidine is to provide long-term immunomodulation and targeted anti-inflammatory action to manage chronic immune responses. Sulfasalazine interferes with key inflammatory pathways. This action helps control the excessive signaling that characterizes chronic inflammation. The medication’s primary benefit is aimed at helping to stabilize the underlying disease and maintaining periods of reduced disease activity, preventing the progressive physical damage associated with these conditions.

Regulatory References

  1. Sulfasalazine: MedlinePlus Drug Information

What side effects are possible with Azulfidine?

Possible Side Effects and Safety Information: Azulfidine (Sulfasalazine)

Azulfidine (sulfasalazine) is a medication used to treat conditions like ulcerative colitis and rheumatoid arthritis. While generally well-tolerated, it can cause a range of side effects. Patients should be aware of these possibilities and discuss any concerns with their healthcare provider.


Common Side Effects

These effects are generally mild and may subside with continued use or a dosage adjustment.

System Side Effect
Gastrointestinal Nausea, vomiting, stomach discomfort, loss of appetite
Central Nervous System Headache
Other Reversible male infertility (lowered sperm count), skin discoloration (yellow-orange) of skin and urine

Serious or Less Common Side Effects

Immediately contact your doctor if you experience signs of these more severe reactions.

  • Blood Disorders: Sulfasalazine can rarely cause serious blood dyscrasias, including agranulocytosis, aplastic anemia, and hemolytic anemia. Symptoms may include fever, sore throat, or unusual bleeding/bruising.
  • Hypersensitivity Reactions: These include Stevens-Johnson syndrome and Toxic Epidermal Necrolysis (severe skin reactions), drug rash with eosinophilia and systemic symptoms (DRESS), and serum sickness-like reactions. Signs include rash, fever, swollen lymph nodes, and liver inflammation.
  • Hepatotoxicity: Liver injury may occur, indicated by jaundice (yellowing of the skin/eyes), dark urine, or persistent nausea/vomiting.
  • Renal Effects: Kidney damage, crystalluria, and nephrotic syndrome have been reported.

Safety Considerations

Azulfidine is contraindicated in patients with a known sulfonamide or salicylate hypersensitivity, and in patients with porphyria or intestinal/urinary obstruction. Close monitoring of complete blood counts and liver/kidney function tests is essential before starting treatment and periodically throughout therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

When Azulfidine (Sulfasalazine) overdose is suspected, regulatory information documents specific clinical manifestations and strictly mandated emergency actions. Documented overdose presentations primarily involve gastrointestinal symptoms, such as nausea, vomiting, gastric distress, and abdominal pains. Central Nervous System effects, including drowsiness and convulsions, have also been reported. The severity of toxicity is chemically linked to the level of the metabolite, total serum sulfapyridine concentration, which is used to monitor the progress of recovery. Severe systemic outcomes, including renal damage, liver damage, and irreversible neurological or neuromuscular changes, are listed as potential risks associated with severe toxicity.

The official overdose profile strictly mandates immediate emergency medical response. Regulatory guidance requires seeking emergency medical attention or calling the Poison Help line. Immediate emergency services (911) must be contacted if acute, life-threatening symptoms occur, specifically for collapse, a seizure, trouble breathing, or inability to be awakened. No specific antidote is known for Sulfasalazine overdose. Management focuses on supportive and symptomatic care, including procedures such as gastric lavage, alkalinizing the urine, and, when indicated, the use of dialysis to facilitate the removal of the drug and its metabolites from the system.

Therapeutic Uses of Azulfidine

What Azulfidine Treats: Main Uses and Benefits

Azulfidine (Sulfasalazine) is commonly used across two main therapeutic domains involving chronic inflammatory or irritative processes. It is generally applied in clinical settings involving heightened systemic burden where supportive symptom management is appropriate. The medication is considered relevant for: Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Ulcerative Colitis (UC).

Managing Symptoms and Supporting Relief

Azulfidine is considered relevant in managing long-term inflammatory joint diseases, where it addresses persistent symptomatic patterns, including pronounced joint pain, swelling, and noticeable stiffness. In these chronic conditions, its core therapeutic contribution assists with maintaining functional stability and may help reduce the impact of disease progression on the joints. In the context of Ulcerative Colitis, it helps address symptoms that interfere with daily functioning, such as persistent diarrhea, abdominal pain, and rectal bleeding. The medication is applied during phases when symptoms become more noticeable to support the patient during difficult episodes and is also used as a maintenance treatment, providing support that helps ease the overall symptom burden and helps sustain periods of symptom stability.

Quick Fact Relief for Symptom
Primary Domain Chronic Inflammatory Bowel Disease
Symptom Focus Managing symptoms related to inflammatory or irritative states
Patient Benefit Helping to maintain a sense of stability when symptoms are more noticeable

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Azulfidine?

Azulfidine (sulfasalazine) eligibility is strictly defined by regulatory authorities based on age, allergies, and pre-existing medical conditions.


Absolute Contraindications

The medicine is contraindicated and must not be used by patients who have:

  • Known hypersensitivity or allergy to sulfasalazine, its metabolites, sulfonamides, or salicylates.
  • A history of porphyria.
  • Intestinal or urinary obstruction.
  • Are pediatric patients under two (2) years of age.

Population-Specific Limitations

Population Group Eligibility Status
Adults Use is allowed for approved indications.
Children 6 years and older Use is allowed for approved indications (e.g., Polyarticular Juvenile Idiopathic Arthritis).
Impaired Organ Function Use requires caution and critical appraisal in patients with impaired hepatic or renal function.
Pregnancy Use is categorized as conditional and only if clearly needed; high-dose folic acid supplementation is advised.
Breastfeeding Use requires caution, especially with premature infants or those with G6PD deficiency.

For children between two and six years of age, the safety and effectiveness for ulcerative colitis have not been established.

What should I know about interactions with other medicines?

Azulfidine Interactions with other medicines and products

Azulfidine (Sulfasalazine) interactions are formally documented by regulatory authorities, focusing on changes in the exposure of co-administered medicines, nutrients, and substances critical for the body. The regulatory profile defines specific combination cautions and constraints on administration.

Interaction Type Interacting Medicines and Substances Official Constraint or Finding
Exposure Alteration Digoxin, Cyclosporine Reduced absorption of Digoxin has been reported, potentially leading to non-therapeutic levels. Cyclosporine levels may also be reduced due to a documented cytochrome P450 interaction.
Pharmacodynamic Risk Azathioprine, 6-Mercaptopurine Sulfasalazine inhibits the TPMT enzyme. Co-administration increases the systemic exposure of these myelotoxic agents, elevating the risk of bone marrow suppression and leukopenia.
Nutrient Interference Folic Acid, Iron, Calcium Gluconate Azulfidine inhibits the absorption and metabolism of Folic Acid, potentially leading to deficiency. Co-administration with Iron or Calcium Gluconate is reported to reduce the absorption of Sulfasalazine itself due to chelation.
Contraindication/Timing Methenamine, Live Typhoid Vaccine Co-administration with Methenamine is not recommended due to an increased risk of crystalluria. A time interval of at least 24 hours is advised between Azulfidine and the Live Typhoid Vaccine.

Regulatory documents also note that the risk of adverse reactions is heightened for individuals who are slow acetylators, a population-specific caution related to the prolonged half-life of the metabolite sulfapyridine. Furthermore, the drug and its metabolites may interfere with certain laboratory assays that measure ultraviolet absorbance.

Mechanism of Action

How Azulfidine Works

Pro-Drug Activation and Dual Site Mechanism

The active ingredient, sulfasalazine, is an inactive pro-drug that requires cleavage by bacterial azoreductase in the colon to release its two active components: 5-aminosalicylic acid (5-ASA) and sulfapyridine. This dual activation mechanism ensures that 5-ASA acts locally on the intestinal lining, resulting in localized modulation of inflammatory processes, while sulfapyridine is absorbed systemically to provide broader immunomodulation.

Suppression of Core Inflammatory Pathways

The 5-ASA metabolite targets key signaling pathways to reduce the synthesis and release of inflammatory mediators. It acts as a non-competitive inhibitor of Lipoxygenase (LO) enzymes, which reduces the creation of pro-inflammatory Leukotrienes. Furthermore, it suppresses the activation of Nuclear Factor kappa-B ( NF-kappa B), limiting the cellular transcription of inflammatory genes, which contributes to limiting the migration of inflammatory cells and modulating heightened physiological responses.

Modulation of Systemic Immune Function

Once absorbed, the sulfapyridine metabolite acts systemically to modulate the adaptive immune response. It suppresses the function of T and B immune cells and reduces the systemic release of inflammatory cytokines ( TNF-alpha, IL-6). The mild anti-folate effect acts to limit the proliferation of immune cells, resulting in a modulated immune response that affects systemic physiological activity.

Dosage and Administration Information

Official Administration Protocol for Azulfidine (Sulfasalazine)

Azulfidine is administered exclusively by the oral route and is available as standard tablets and specialized enteric-coated tablets (gastro-resistant tablets), typically in 500 mg strength. Proper administration relies on a gradual dose titration and specific timing in relation to meals.

Treatment for all approved indications begins with a low daily dose that is slowly increased over several days or weeks to reach the full maintenance or induction dose. This gradual increase helps to mitigate potential gastrointestinal intolerance.


Dosing and Scheduling Principles

Administration requires taking the tablets with food, preferably after meals, and the total daily amount must be divided into evenly spaced doses throughout the day and night to ensure consistent drug levels. For Ulcerative Colitis, the initial induction dose of 3 to 4 grams (g) daily is reduced to a maintenance dose of 2 g daily upon achieving remission, and maintenance therapy is often continued long-term.

For Rheumatoid Arthritis, the maintenance dose is typically 2 g daily, achieved by gradually escalating from an initial 0.5 to 1.0 g per day. Clinical response for this condition may require up to 12 weeks of consistent use before therapeutic benefit is assessed.


Handling and Procedural Rules

The enteric-coated tablets must be swallowed whole; they should not be crushed, broken, or chewed, as this compromises the specialized delivery system intended to release the drug in the lower bowel. Adequate fluid intake should also be maintained throughout the course of treatment. If a scheduled dose is missed, it should be taken as soon as remembered, unless it is almost time for the next dose, in which case the missed dose is skipped without doubling the next dose.

Recent Clinical Evidence

Research Evidence Overview for Azulfidine (Sulfasalazine)


Evidence for use in Rheumatoid Arthritis (RA)

Research exploring Azulfidine for Rheumatoid Arthritis (RA) has primarily involved randomized, double-blind, placebo-controlled trials (RCTs). These studies compare the results observed in patients receiving the medication against those receiving an inactive placebo pill to examine patterns of change in measured outcomes. The research examined specific outcomes, including tender and swollen joint counts, duration of morning stiffness, and other patient-reported outcomes describing perceived discomfort and functional imbalance.

Studies monitored and reported data show patterns related to changes in these core RA measures in the study populations. When aggregated into systematic reviews and meta-analyses, the findings describe patterns observed in the studies compared to placebo measurements over defined, typically short-term, time intervals. Long-term outcomes are not fully established regarding physical function and patterns of long-term joint integrity over many years, as studies focused mainly on immediate or short-term changes. Furthermore, comparative evidence is lacking for Sulfasalazine against some of the newest classes of DMARDs now available for RA.


Evidence for use in Ulcerative Colitis (UC)

For Ulcerative Colitis (UC), research was studied for two key areas: examining the response during periods of heightened symptom activity (active disease) and observing the patterns during phases of stability and flare-ups (maintenance of remission). The evidence base includes numerous randomized controlled trials, and the medication was studied for research exploring comparisons between Azulfidine, placebo, and similar medications (5-ASAs).

Data for certain groups remain insufficient; research mainly focused on patients with mild to moderate disease. The studies describe that in the observed populations, research explored and reported patterns observed in the studies related to outcomes of symptom stability and the avoidance of disease exacerbation when compared against placebo over defined treatment periods.


Evidence in Juvenile Idiopathic Arthritis (JIA)

Research exploring Azulfidine in Polyarticular Juvenile Idiopathic Arthritis (PJIA) mainly involved a limited number of placebo-controlled RCTs and long-term observational follow-up studies of the pediatric cohort. The results apply only to the populations studied (typically ages 6 and older), as safety and effectiveness are not established in children younger than 6 years of age. Subgroup findings are uncertain regarding patterns observed in older adults or patients with specific, complex pre-existing conditions.

Key Studies & References

  1. Sulfasalazine for treating rheumatoid arthritis (Review) - Cochrane Review Summary on efficacy and toxicity

Frequently Asked Questions (FAQ)

Common questions about Azulfidine (FAQ)

Q: Why is Azulfidine prescribed for both arthritis and inflammatory bowel disease?

Regulatory documents state that Azulfidine (sulfasalazine) is officially approved for the treatment of Ulcerative Colitis and for managing certain forms of Rheumatoid Arthritis (RA) in adults and Juvenile Idiopathic Arthritis (JIA) in children. Official guidance indicates this dual action in the body is responsible for its use in both conditions.


Q: What is the typical time frame to start feeling better after starting Azulfidine?

Azulfidine is a Disease-Modifying Anti-Rheumatic Drug (DMARD) that is designed to work over time. For arthritis conditions, official clinical studies indicate that a therapeutic response may require up to 12 weeks of consistent use before a full assessment of improvement can be made.


Q: Can Azulfidine cause my skin to be more sensitive to the sun?

Yes, official drug information indicates that photosensitivity (increased sensitivity to sunlight) has been reported with the use of Azulfidine. Official product information suggests patients should take precautions, such as limiting sun exposure, using sunscreen, and wearing protective clothing outdoors.


Q: Does Azulfidine affect fertility or planning to conceive?

The drug is known to be associated with reversible male infertility, often resulting in a reduced sperm count and abnormal sperm forms. The effects typically appear to be reversible upon discontinuing the medication. Official information does not indicate a demonstrated effect on female fertility.


Q: Is it necessary to get blood tests done regularly while on Azulfidine?

Yes, official regulatory information requires close monitoring. Patients must have their complete blood counts and liver and renal function tests checked before starting treatment and then periodically throughout the course of therapy. This monitoring is required to detect potential rare but serious side effects like blood disorders or liver injury.


Q: How does Azulfidine affect the liver or kidneys?

Studies and official information indicate that serious, though uncommon, adverse reactions including liver injury (hepatotoxicity) and various forms of kidney injury (renal effects) have been reported. Due to these potential effects, official safety information advises caution and close monitoring for individuals with pre-existing impaired liver or kidney function.


Q: What happens if I accidentally miss a dose of Azulfidine?

According to patient information leaflets, if a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped. Regulatory guidance states that a missed dose should not be doubled.


Q: Are there any specific vaccines I should avoid while taking Azulfidine?

Regulatory guidance suggests an interval may be necessary between this drug and the Live Typhoid Vaccine. Additionally, official information notes that the Varicella (chickenpox) vaccine should be avoided within six weeks of use, as there is a reported risk of Reye's syndrome.


Q: How long do most people need to stay on Azulfidine treatment?

The required duration of treatment varies based on the condition being treated. For Ulcerative Colitis, maintenance therapy is often continued for the long term after disease remission is achieved. For inflammatory arthritis conditions, the length of treatment is determined by the ongoing therapeutic response.


Q: Can I take Azulfidine with common pain relievers like ibuprofen?

Official documents caution that taking Azulfidine with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen may potentially increase the risk of certain side effects. Official information suggests cautious monitoring may be appropriate when this combination is used.


Q: Can people with a history of kidney stones take Azulfidine?

Azulfidine has been reported to cause crystalluria and nephrolithiasis (kidney stones). Due to this risk, official information indicates that caution and close renal monitoring are appropriate for individuals with a history of kidney disease.


Q: Is a metallic taste in the mouth a known side effect of Azulfidine?

Yes, a change in the way things taste, including the development of a metallic taste in the mouth, has been reported in clinical experience as a possible side effect of the medication.


Q: Is it necessary to avoid sunlight while taking Azulfidine?

Yes, due to the risk of photosensitivity (increased sensitivity to the sun), regulatory information suggests limiting unnecessary exposure to natural sunlight, sunlamps, and tanning beds while taking Azulfidine.


Q: Does Azulfidine affect my energy levels or cause tiredness?

Official adverse reaction reports do not consistently list common fatigue or tiredness as a primary side effect, though related central nervous system effects like headache and dizziness are reported. However, if severe adverse reactions like blood disorders occur, unusual weakness and tiredness can be a symptom.


Q: What if I'm already taking medicine for acid reflux; can I still take Azulfidine?

Official drug interaction documents caution that co-administration with substances like Iron and Calcium Gluconate can reduce the absorption of Azulfidine. As with any concurrent oral medication, it is important to confirm compatibility.


Q: Do I need to take Azulfidine with food, and does it matter what kind of food?

The official administration protocol advises that the tablets should be taken with food, preferably after meals, along with a full glass of water. Taking the medication with food helps minimize potential gastrointestinal side effects. No specific food type (e.g., fat or protein content) is mandated.


Q: Why do doctors often start with a low dose of Azulfidine and gradually increase it?

Official administration instructions emphasize starting with a low daily dose that is gradually increased over several days or weeks. This dose titration strategy is used to minimize the risk and severity of common gastrointestinal side effects while the body adjusts to the medicine.


Q: Is it normal to have hair loss after starting Azulfidine?

Official regulatory data includes alopecia (hair loss) as an adverse reaction observed in clinical trial data, although it is generally not reported as a common or frequent side effect among patients.


Q: Why is it important to stay well-hydrated while taking Azulfidine?

It is important to maintain adequate fluid intake because the drug and its components can crystallize in the urinary tract. This increased hydration helps prevent the formation of crystalluria or kidney stones.


Q: Are there any food restrictions I need to follow while taking Azulfidine?

There are no general food restrictions. However, the drug is known to inhibit the body's absorption and metabolism of Folic Acid (Vitamin B9), which is why supplementation is often required. Additionally, taking the medicine simultaneously with supplements containing Iron or Calcium Gluconate may reduce the absorption of the Azulfidine itself.


Q: Can I take Azulfidine while pregnant?

The use of Azulfidine during pregnancy is categorized as conditional; official guidance states its use is appropriate only if the clinical need is clearly established. Because the drug can interfere with the body's folic acid levels, high-dose folic acid supplementation is strongly advised throughout the pregnancy.


Q: Does Azulfidine interfere with over-the-counter vitamins or supplements?

Official interaction documents note that Azulfidine interferes with the absorption and metabolism of Folic Acid, making supplementation necessary for many patients. Furthermore, co-administration with supplements containing Iron or Calcium Gluconate may reduce the absorption of the Azulfidine itself.

How should Azulfidine be stored and disposed of?

Storage and Stability

Official regulatory guidelines require Azulfidine (Sulfasalazine) tablets to be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from both light and excessive moisture to preserve its stability.

To comply with these requirements, the medication must be kept in its original container and the container must remain tightly closed. Temperature excursions are permitted between 15 C and 30 C.

Child Safety and Disposal

For safety, Azulfidine must always be stored out of the sight and reach of children.

When disposing of unused or expired tablets, patients must follow local community regulations. The medication should not be flushed down a toilet or poured into a drain unless specific instructions from a regulatory authority permit this action.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azulfidine found in:

A-Z Index: